Cannabis Law Report
JUNE 14, 2022
There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. We will be joined by excellent speakers including Dr. Thomas Insel – Former Director of the US National Institute of Mental Health (2002 – 2015), Prof. David Nutt and Prof.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 17, 2022
A 2002 study found that smoking cannabis increased blood flow in the frontal lobe, an area that’s thought to play an important role in abstract thought, creative thinking and sensory processing. 15 Multiple clinical trials have shown that linalool in ylang ylang oil and lavender oil “significantly increased calmness.”
Cannabis Law Report
JULY 9, 2021
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
The Cannigma
AUGUST 14, 2022
A 2002 study found that cannabis increases blood flow to the frontal lobe of the brain. 11 Multiple clinical trials have shown that linalool in ylang ylang oil and lavender oil, which are both high in linalool “significantly increased calmness” which can help an overactive brain settle down and focus.
The Cannigma
DECEMBER 12, 2022
Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. As such, there have been numerous clinical trials using ketamine.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Patients can legally access medicinal cannabis through a doctor, via the TGA’s Authorised Prescribers and Special Access schemes.
Expert insights. Personalized for you.
52 
Let's personalize your content